<DOC>
	<DOCNO>NCT01403610</DOCNO>
	<brief_summary>The Primary Objectives : - To determine extent TH-302 able penetrate blood brain barrier affect tumor tissue - To assess safety single dose TH-302 patient high grade glioma undergo surgery - To assess safety TH-302 combination bevacizumab patient high grade glioma - To determine MTD DLT ( ) TH-302 combination bevacizumab The Secondary Objectives : To determine progression-free survival without debulking craniotomy patient treat combination bevacizumab TH-302 follow recurrence single agent bevacizumab</brief_summary>
	<brief_title>Safety Efficacy Study TH-302 CNS Penetration Recurrent High Grade Astrocytoma Following Bevacizumab</brief_title>
	<detailed_description>Single center , dose-escalation , prospective study TH-302 single dose 575 mg/m2 placebo administer preoperatively , follow postoperative combination therapy bevacizumab 10mg/kg every 2 week TH-302 240 - 670 mg/m2 every 2 week ( 4 week cycle ) disease progression . Subjects randomize ( 2:1 ) receive pre-operative dose TH-302 ( surgical subject ) . Subjects receive surgery receive combination therapy bevacizumab 10 mg/kg every 2 week TH-302 240-670 mg/m2 every 2 week ( 4 week cycle ) start Cycle 1 , Day 1 disease progression . This study use classic dose escalation design determine MTD TH-302 use combination bevacizumab . The dose TH-302 escalate cohort 3-6 subject . The initial dose TH-302 240 mg/m2 . A dose level minus 1 built study event subject experience excessive toxicity Dose Level 1 . Dose escalation continue 340 mg/m2 670 mg/m2 .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Phosphoramide Mustards</mesh_term>
	<criteria>1 . At least 18 year age 2 . Ability understand purpose risk study sign write informed consent form approve investigator 's IRB/Ethics Committee 3 . Histologically confirm high grade astrocytoma 4 . Progression follow standard combine modality treatment radiation temozolomide chemotherapy , well antiangiogenic therapy ( ie , bevacizumab ) 5 . Recovered toxicity prior therapy grade 0 1 6 . ECOG performance status 0 1 7 . Life expectancy least 3 month 8 . Acceptable liver function 9 . Acceptable renal function 10 . Acceptable hematologic status 11 . All woman childbearing potential must negative serum pregnancy test male female subject must agree use effective mean contraception ( surgical sterilization use barrier contraception either condom diaphragm conjunction spermicidal gel IUD ) partner entry study 6 month last dose 1 . The subject receive warfarin ( coumarin derivative ) unable switch low molecular weight heparin ( LMWH ) first dose study drug . 2 . The subject evidence acute intracranial intratumoral hemorrhage either MRI computerize tomography ( CT ) scan . Subjects resolve hemorrhage change , punctate hemorrhage , hemosiderin eligible . 3 . The subject unable undergo MRI scan ( eg , pacemaker ) . 4 . The subject receive enzymeinducing antiepileptic agent within 14 day study drug ( eg , carbamazepine , phenytoin , phenobarbital , primidone ) . 5 . The subject recover National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) v4.0 Grade â‰¤ 1 AEs ( except alopecia , anemia lymphopenia ) due surgery , antineoplastic agent , investigational drug , medication administer prior study drug . 6 . The subject evidence wind dehiscence 7 . Severe chronic obstructive pulmonary disease hypoxemia ( require supplementary oxygen , symptom due hypoxemia oxygen saturation &lt; 90 % pulse oximetry 2 minute walk ) opinion investigator physiological state likely cause normal tissue hypoxia 8 . The subject pregnant breastfeeding . 9 . The subject serious intercurrent illness 10 . The subject inherit bleed diathesis coagulopathy risk bleeding . 11 . The subject receive follow prior anticancer therapy : Nonstandard radiation therapy brachytherapy , systemic radioisotope therapy ( RIT ) , intraoperative radiotherapy ( IORT ) . Note : stereotactic radiosurgery ( SRS ) allow Antiangiogenic agent whose primary mode action VEGF signal within 21 day prior first dose study drug ( surgical subject ) Nonbevacizumab systemic therapy ( include investigational agent smallmolecule kinase inhibitor ) noncytotoxic hormonal therapy ( eg , tamoxifen ) within 7 day 5 halflives , whichever short , prior first dose study drug Biologic agent ( antibody , immune modulators , vaccine , cytokine ) within 21 day prior first dose study drug Nitrosoureas mitomycin C within 42 day , metronomic/protracted lowdose chemotherapy within 14 day , cytotoxic chemotherapy within 28 day , prior first dose study drug Prior treatment carmustine wafer Prior treatment TH302</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>TH-302</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Phase 2</keyword>
	<keyword>Glioma</keyword>
	<keyword>High Grade Glioma</keyword>
	<keyword>CNS</keyword>
</DOC>